[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"prediabetic-state-igt\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:prediabetic-state-igt":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100635795","intestinal-endotoxemia-and-beta--cell-dysfunction-in-prediabetics-100635795",false,"NCT07557329","Intestinal Endotoxemia and Beta- Cell Dysfunction in Prediabetics","Association Between Intestinal Endotoxemia and Beta-Cell Dysfunction in Lean Prediabetics","Inclusion Criteria:\n\n* Age: 18-65 years\n* BMI: 18.5-24.9 kg\u002Fm²\n* ADA prediabetes: FPG 100-125 mg\u002FdL OR 2hPG 140-199 mg\u002FdL OR HbA1c 5.7-6.4%\n* HOMA-IR \\\u003C1.5 (key inclusion criterion)\n\nExclusion Criteria:\n\n* \\- HOMA-IR ≥1.5\n* BMI ≥25 kg\u002Fm²\n* Diabetes, acute inflammation, GI disorders (Table 1) Group II (Controls): Lean normoglycemic ; age and sex-matched healthy subjects",true,"ALL","18 Years","65 Years",{"count":21,"type":22},120,"ESTIMATED","OBSERVATIONAL","the goal of this observation study is to learn about association between intestinal endotoxemia and prediabetes lean patients with the aim of prevention of diabetes in those category of patients",[26,27],"Prediabetic State (IGT)","Prediabetic State","NOT_YET_RECRUITING","2026-04-29",{"date":31,"type":32},"2026-05-05","ACTUAL",{"date":34,"type":22},"2026-05",{"date":36,"type":22},"2027-06",{"name":38,"class":39},"Sohag University","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":56,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100573784","phase-4-the-effects-of-xuezhikang-and-atorvastatin-on-lipid-in-patients-with-dyslipidemia-and-prediabetes-100573784","NCT06750783","The Effects of Xuezhikang and Atorvastatin on Lipid in Patients With Dyslipidemia and Prediabetes","A Randomized Controlled Study on the Effects of Xuezhikang and Atorvastatin on Blood Glucose and Lipid Levels in Patients With Dyslipidemia and Prediabetes","Xuezhikang","Inclusion Criteria:\n\n* Age ≥ 18 years old;\n* No gender restrictions;\n* Definition of pre diabetes: All subjects were tested with 75g OGTT to measure fasting and 2h venous serum glucose and glycosylated hemoglobin. Fasting blood glucose ≥ 6.1 and \\\u003C 7mmol\u002FL, 2-hour serum glucose ≥ 7.8 and \\\u003C 11.1mmol\u002FL after glucose load, and glycated hemoglobin\\\u003C6.5%;\n* Abnormal lipid metabolism: LDL-c ≥ 3.4 mmol\u002FL and\\\u003C4.9 mmol\u002FL, and TG ≤ 5.6 mmol\u002FL; (2) Non-HDL-c ≥ 4.1mmol\u002FL and\\\u003C5.7 mmol\u002FL, and TG ≤ 5.6 mmol\u002FL;\n* Voluntarily sign the informed consent form.\n\nExclusion Criteria:\n\n* Patients who have met the diagnosis of diabetes;\n* Within 3 months prior to signing the informed consent form, there was an acute coronary syndrome, stroke, or transient ischemic attack.\n* ALT\u002FAST\\>3 times ULN;\n* Known myopathy, rhabdomyolysis, or creatine kinase levels greater than 4-fold ULN, and not caused by muscle injury;\n* Pregnant or planning to conceive;\n* Have used any lipid-lowering drugs within 3 months;\n* Individuals with allergies\u002Fcontraindications to Xuezhikang and Atorvastatin.\n* Suffering from any of the following diseases: uncontrolled hyperthyroidism and hypothyroidism, severe heart failure, malignant tumors, hematopoietic system diseases, digestive system diseases affecting digestion and\u002For absorption function, mental disorders, other serious or unstable physical diseases.\n* History of alcohol or drug abuse or dependence within 3 months prior to joining the trial.\n* Participated in clinical trials of other drugs or devices within 3 months prior to joining the trial.\n* Researchers believe that other situations are not suitable for participating in the experiment.",{"count":50,"type":22},398,"INTERVENTIONAL",[53],"PHASE4","This study compares the impact of Xuezhikang and atorvastatin on glucose metabolism to explore the incidence of prediabetes patients developing diabetes after 24 weeks of Xuezhikang use, and by investigating the effect of Xuezhikang on blood glucose fluctuations, discusses the possible mechanisms by which Xuezhikang affects glucose metabolism.",[26],[57,58,59,60,61],"XUEZHIKANG","atorvastatin","glucose metabolism","blood glucose fluctuations","diabetes","RECRUITING","2025-04-01",{"date":65,"type":32},"2025-04-03",{"date":67,"type":32},"2024-12-31",{"date":69,"type":22},"2026-03-31",{"name":71,"class":39},"Beijing Tsinghua Chang Gung Hospital",3]